Company Overview
Auna S.A. operates as a healthcare service provider with a physical presence in Mexico, Peru, and Colombia, offering hospitals, clinics, prepaid healthcare plans, dental and vision insurance, and pharmaceutical sales. This business model places the entity squarely within the Healthcare sector, specifically the Medical Care Facilities industry, where it competes to deliver essential medical services and insurance coverage. The company's market capitalization stands at $442.60M, while its trailing twelve-month revenue reaches $4.39B, though the employee count is not publicly disclosed. These financial figures indicate a significant operational scale within the Latin American healthcare market, suggesting the organization manages substantial assets and revenue streams despite the lack of specific headcount data. The disparity between the multi-billion dollar revenue and the sub-$500M market cap highlights a valuation structure common in capital-intensive healthcare infrastructure plays, where asset-heavy operations often result in lower price-to-book multiples relative to their revenue generation capabilities.
Financial Health
The company reported total revenue of $4.39B for the trailing twelve months, generating a net income of $97.61M and an EBITDA of $819.49M. The substantial gap between the $4.39B revenue and the $97.61M net income reveals a cost structure where operating expenses, likely including high fixed costs associated with hospital maintenance and staff, consume a significant portion of top-line growth. Free cash flow stands at $47.48M, which represents the cash remaining after capital expenditures and operating costs, indicating a modest level of financial flexibility for debt servicing or strategic investments. The company maintains a cash balance of $365.00M against total debt of $3.94B, resulting in a debt-to-equity ratio of 223.10% which characterizes a highly leveraged balance sheet rather than a conservative one. Liquidity is assessed via a current ratio of 1.11, suggesting the company holds just enough current assets to cover its current liabilities, indicating tight but manageable short-term liquidity conditions. Return on Equity is 6.5% and Return on Assets is 5.4%, metrics that suggest capital efficiency is constrained by the high debt load, as the returns generated on equity and assets are relatively low when compared to the leverage employed.
Valuation Assessment
The stock trades with a P/E Ratio of 16.16 on a trailing twelve-month basis and a Forward P/E of 5.23. The significant divergence between the trailing and forward P/E ratios implies that the market expects earnings to grow substantially in the future, or that the current earnings are depressed relative to the forward-looking estimates. The Price to Book ratio is 0.98, indicating that the market values the company at roughly parity with its book value, suggesting no significant market premium for its intangible assets or growth prospects. Alternative valuation metrics include a Price to Sales ratio of 0.10 and an EV/EBITDA of 5.11, figures that suggest the stock is priced at a discount relative to its sales and earnings power, a common characteristic for asset-heavy or highly leveraged healthcare operators. The 52-week high is $7.50 and the low is $4.46; without a specific current price, the range establishes the volatility envelope within which the stock has traded over the last year. The Beta of 2.10 indicates that the stock is significantly more volatile than the broader market, moving more than twice as much as the index in either direction during periods of market stress or gain.
Growth & Income
Revenue growth for the trailing twelve months is 6.6%, while earnings growth for the year-over-year period is not available due to the absence of prior year comparative data in the provided metrics. In the absence of reported earnings growth figures, it is impossible to determine if earnings are growing faster or slower than revenue, but the 6.6% revenue expansion demonstrates top-line momentum in a competitive healthcare landscape. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available earnings into operations, debt reduction, or growth initiatives rather than distributing cash to shareholders. This non-dividend profile aligns with the high debt levels and the need for capital to service the $3.94B debt load, prioritizing financial stability and operational expansion over immediate shareholder income. The overall growth and income profile is defined by moderate revenue expansion and a reinvestment strategy that supports a highly leveraged capital structure without providing current income yields.